The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment
For a significant proportion of patients with inflammatory bowel disease (IBD), primary non-response and secondary loss of response to treatment remain significant issues. Anti-tumor necrosis factor therapies have been licensed for use in IBD. Other disease-related pathways have been targeted as wel...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
MDPI AG
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/94e901fc212c42a2bfbcb2265d38a2d7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|